新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 礼来 » 重磅抗癌药Erbitux移交礼来 百时美专注免疫肿瘤学业务

重磅抗癌药Erbitux移交礼来 百时美专注免疫肿瘤学业务

来源:生物谷 2015-04-17 09:57

2015年4月17日讯 /生物谷BIOON/ --爱必妥(Erbitux)是全球十大畅销抗癌药之一,多年来百时美施贵宝(BMS)一直负责该药在美国的销售。然而现在,百时美一门心思专注火爆的免疫肿瘤学,不再钟情于Erbitux,并且要把它移交给礼来(Eli Lilly)。Erbitux原本由ImClone公司研制,之后与百时美施贵宝和德国默克达成了研发及营销协议。礼来在2008年耗资65亿美元收购ImClone后将Erbitux收入囊中。

在昨日的一份声明中,百时美表示,对Erbitux长达14年所取得的销售成绩无比骄傲。百时美此次将Erbitux北美市场营销权移交礼来,也意味着其进一步调整肿瘤学业务,使之更好地与横跨实体瘤和恶性血液病等免疫肿瘤学领域的优先研发机会匹配。

2家制药公司表示,礼来将接手Erbitux在美国、加拿大、波多黎各的销售,这些地区在2014年的销售额为7.23亿美元,2013年的销售额为6.93亿美元。此外,礼来也将完全负责Erbitux的生产。百时美施贵宝发言人Ken Dominski表示,此次移交Erbitux权利后,将对美国和波多黎各进行小范围裁员。

该笔资产移交预计将在今年第四季度完成,不过百时美将获得分层特许权使用费直至2018年。另外,今年2月,百时美将Erbitux在日本的营销权转让给了德国默克,双方之前是共同负责该市场的销售。

百时美之所以作此决定,是因为该公司要把大部分金钱和精力转移到免疫肿瘤学领域,如肿瘤免疫疗法PD-1抑制剂Opdivo,这类疗法能够利用机体免疫系统对抗肿瘤。去年12月,Opdivo收获了黑色素瘤适应症,今年3月,又收获了肺癌适应症。目前,百时美正在广泛的肿瘤类型中,调查Opdivo单药和各类组合疗法,以深挖Opdivo的临床潜力。最近,汤姆森路透把Opdivo列入了《2015年重磅药品预测名单》榜首,预测该药在2019年的销售额将高达56.8亿美元。

至于礼来,该公司表示非常欢迎Erbitux的回归。如果拿回美国的销售权,Erbitux现在将成为礼来的重磅产品之一。礼来肿瘤学总裁Sue Mahony在一份声明中表示,完全将Erbitux收入礼来的肿瘤学产品组合,将增强公司在胃肠道癌症及头颈癌领域的领导地位。(生物谷Bioon.com)

英文原文:BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly

Bristol-Myers Squibb recently gave Erbitux marketing in Japan to German Merck

Erbitux is one of the top 10 best selling cancer drugs in the world and for years Bristol-Myers Squibb ($BMY) has sold it in the U.S. But Erbitux no longer fits in the sweet spot for Bristol-Myers which is hot for immuno-oncology right now and so is turning over marketing of the colorectal cancer drug to others. In the U.S. that is Eli Lilly ($LLY), whose ImClone unit developed the cancer drug and put the marketing deal in place before Lilly bought ImClone some years back.

Bristol-Myers Squibb is "incredibly proud" of what it has accomplished with Erbitux in the 14 years it has been selling it, Murdo Gordon, head of worldwide markets, said in a statement, adding that the "agreement further aligns our oncology organization with our prioritized opportunities in immuno-oncology, across both solid tumors and hematologic malignancies."

The two drugmakers said today that Lilly will assume Erbitux marketing in the U.S., Canada and Puerto Rico, where it had sales last year of $723 million, up from $693 million the year before. Lilly also assumes full responsibility for manufacturing, although ImClone already makes the drug for the U.S. BMS spokesman Ken Dominski said that the company expects "a very small number of individuals" in the U.S. and Puerto Rico to be laid off as a result of the move.

The changeover, which comes after BMS sold the drug for 14 years, is expected to be complete in the fourth quarter, although BMS will receive tiered royalty payments into 2018. Bristol-Myers in February turned over marketing rights to the drug in Japan to Merck KGaA, where the two had shared that responsibility.

The move comes as Bristol-Myers Squibb, like others, has been putting much of its oncology focus, and lots of money, into immuno-oncology treatments that get the immune system to attack tumors, like its PD-1 inhibitor Opdivo. Recently approved to treat lung cancer after already being approved by the FDA for melanoma, Opdivo was recently put at the top of Thomson Reuters' blockbusters-to-be list for 2015, with a 2019 sales forecast of $5.68 billion.

As for Lilly, the company says it is nice to have Erbitux back in the fold. Lilly has been earning about $373 million from marketing arrangements for the drug for several years. If U.S. sales hold, Erbitux could now earn blockbuster numbers for the Indianapolis-based company. Sue Mahony, president of Lilly Oncology, said in a statement that "fully bringing Erbitux into the Lilly Oncology portfolio accelerates Lilly's commitment and leadership in gastrointestinal cancers to include an effective treatment for advanced colorectal cancer as well as head and neck cancer."

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库